Table 2.

Results

MeasureNMean (SD)P Value
Pre-TCZPost-TCZ
Graft function
 eGFR T0 versus T3m1041.6 (18.8043)42.2 (17.6937)0.71
 eGFR T0 versus T6m1041.6 (18.8043)39.2 (19.0193)0.43
 eGFR T0 versus T12m641.7 (20.2846)41 (26.6983)0.88
 Proteinuria T0 and Tc101.61 (1.1426)1.85 (2.3244)0.70
 Slope eGFR (T0−12 m versus T0+12 m)10−0.14 (0.9082)−0.33 (1.0724)0.60
Histology
 MVI64.8333 (1.472)4.1667 (2.0412)0.39
 Total chronicity score64.3333 (1.9664)5.6667 (3.4448)0.29
 IFTA62.5 (0.8367)3.3333 (1.7512)0.38
MMDx scores
 AbMR50.792 (0.1681)0.776 (0.2615)0.86
 Total rejection50.83 (0.1454)0.79 (0.1488)0.51
 Atrophy fibrosis50.362 (0.2374)0.584 (0.1494)0.21
 Global disturbance50.884 (2.243)1.646 (1.2158)0.44
  • TCZ, tocilizumab; T0, at time of initiation of TCZ; T3m, 3 months after initiation of TCZ; Tc, at time of most recent followup; MVI, microvascular inflammation (glomerulitis plus peritubular capillaritis score); IFTA, interstitial fibrosis and tubular atrophy; MMDx, Molecular Microscope Diagnostic System; AbMR, antibody-mediated rejection.